Schroder Investment Management Group Sells 634,571 Shares of uniQure (NASDAQ:QURE)

Schroder Investment Management Group decreased its stake in uniQure (NASDAQ:QURE - Free Report) by 43.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 834,075 shares of the biotechnology company's stock after selling 634,571 shares during the period. Schroder Investment Management Group owned 1.71% of uniQure worth $14,363,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. RTW Investments LP acquired a new position in uniQure during the third quarter valued at approximately $49,000. Quarry LP bought a new stake in shares of uniQure during the 3rd quarter worth approximately $58,000. Twin Tree Management LP bought a new position in shares of uniQure in the fourth quarter valued at $77,000. FNY Investment Advisers LLC acquired a new position in uniQure during the fourth quarter worth $88,000. Finally, China Universal Asset Management Co. Ltd. raised its position in uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 969 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Trading Down 4.8 %

NASDAQ QURE traded down $0.42 on Tuesday, hitting $8.34. The company's stock had a trading volume of 1,217,132 shares, compared to its average volume of 1,679,581. The firm has a market cap of $451.00 million, a PE ratio of -1.68 and a beta of 0.42. The company's 50-day moving average is $12.83 and its 200 day moving average is $11.00. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on QURE shares. StockNews.com upgraded shares of uniQure to a "sell" rating in a research note on Tuesday, March 11th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the company a "neutral" rating in a research note on Thursday, December 12th. Mizuho raised their price objective on uniQure from $7.00 to $20.00 and gave the company a "neutral" rating in a research report on Thursday, December 19th. Leerink Partners boosted their target price on uniQure from $26.00 to $44.00 and gave the stock an "outperform" rating in a report on Wednesday, December 11th. Finally, Chardan Capital began coverage on uniQure in a report on Tuesday, April 1st. They set a "buy" rating and a $38.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, uniQure currently has an average rating of "Moderate Buy" and an average target price of $38.80.

Insider Activity at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the sale, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares of the company's stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 over the last three months. Company insiders own 4.74% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.